Promacta — CareFirst (Caremark)

Initial criteria

• Treatment of myelodysplastic syndromes (MDS)

Reauthorization criteria

• Authorization of 12 months may be granted if member experiences benefit from therapy (e.g., increased platelet counts, decreased bleeding events, reduced platelet transfusion need)

Approval duration

12 months